Kyverna Therapeutics, Inc. (KYTX) fair value analysis
Nasdaq · Updated 2026-10-19
KYTX price how computed
Valuation status
No fair-value estimate yetKYTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for KYTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $5.67
- Sector
- Healthcare
- 12-month range
- $5.67–$11.25
- Market cap
- $351M
- From 52-week high
- -49.6%
- Shares outstanding
- 61.8M
- Rank in Healthcare by quality score
- #246 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company is headquartered in the United States and operates in the healthcare sector.
KYTX currently ranks #246 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $351M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-2.94
- Debt / equity
- 0.20
- Shares outstanding
- 61.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $7.42
- 200-day average
- $8.23
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.0%)
2026-03 ▲ beat (+10.1%)
2025-12 ▲ beat (+7.0%)
2025-09 ▲ beat (+10.5%)
2025-06 ▲ beat (+6.7%)
2025-03 ▼ miss (-3.0%)
2024-12 ▲ beat (+8.7%)
2024-09 ▬ met (0.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $30.4
- Target vs last price
- +436.2%
What our data shows for KYTX
- Shares are trading in the lower third of their 12-month price range of $5.67–$11.25.
- The 14-day relative strength index sits at a neutral 31.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- KYTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the KYTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — KYTX, a Healthcare sector company, showed movement in its relative strength index this week as the RSI zone shifted from oversold to neutral territory. This change in the derived indicator reflects a transition in the stock's momentum dynamics as tracked by TickrTrends. The full valuation verdict for KYTX remains pending.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is KYTX stock undervalued?
TickrTrends has no fair-value estimate for KYTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is KYTX's TickrTrends verdict?
KYTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does KYTX compare to other Healthcare stocks?
KYTX ranks #246 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is KYTX overbought or oversold?
KYTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does KYTX report earnings next?
KYTX's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does KYTX usually beat earnings estimates?
Over its last 8 reported quarters KYTX beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about KYTX?
Of 6 analysts covering KYTX, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $30.4 (+436.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.